Ester Prodrugs for Stable Aqueous Ophthalmic Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension lack effective compounds that are stable in aqueous solutions, limiting their efficacy and stability for ocular conditions.
Innovation Solution
Development of ester compounds that are stable in aqueous solutions, which can be used in pharmaceutical compositions to treat glaucoma, ocular hypertension, and other ocular conditions by reducing intraocular pressure and corneal thickening, and are administered in therapeutically effective amounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional glaucoma treatments are used, then they can treat ocular hypertension, but they lack stability in aqueous solutions
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of carbonic anhydrase inhibitors through esterification, transforming them into prodrugs with improved aqueous stability. The ester groups modify the physicochemical properties of the parent compounds, enabling them to maintain stability in aqueous ophthalmic formulations while retaining therapeutic activity after enzymatic hydrolysis in the eye.
Solution Approach 2:
The patent uses ester prodrugs as intermediary forms of carbonic anhydrase inhibitors. These ester intermediates provide a stable delivery vehicle that can be formulated in aqueous solutions, then converted to the active parent compound through hydrolysis by esterases in the ocular tissues, thus bridging the gap between formulation stability and therapeutic efficacy.
2Reliability
If stable aqueous formulations are developed, then efficacy is improved, but compound stability is limited
Solution Approach 1:
The patent segments the drug molecule into a stable ester prodrug portion and a reactive carbamate portion. The ester segment provides aqueous stability for formulation, while the carbamate segment maintains the carbonic anhydrase inhibitory activity. This segmentation allows the compound to exhibit both stability in formulation and efficacy in treatment.
Solution Approach 2:
The patent creates composite molecular structures by combining ester groups with carbonic anhydrase inhibitor cores. This composite approach integrates the stability-conferring ester functionality with the activity-conferring heterocyclic or aromatic structures, resulting in molecules that possess both formulation stability and therapeutic efficacy.
Data Source
AI summary
The invention provides ester compounds for treating ophthalmic diseases. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.